Neurogene logo

Neurogene share price today

(NGNE)

Neurogene share price is $23.12 & ₹1,983.93 as on 7 Jan 2025, 2.30 'hrs' IST

$23.12

-0.11

(-0.47%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Neurogene share price in Dollar and Rupees. Guide to invest in Neurogene stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Neurogene, along with analyst recommendations, forecasts, and comprehensive financials.

Neurogene share price movements

  • Today's Low: $22.90
    Today's High: $23.99

    Day's Volatility :4.54%

  • 52 Weeks Low: $14.44
    52 Weeks High: $74.49

    52 Weeks Volatility :80.61%

Neurogene Returns

PeriodNeurogene IncIndex (Russel 2000)
3 Months
-53.84%
0.0%
6 Months
-39.35%
0.0%
1 Year
-11.82%
0.0%
3 Years
10.62%
-19.8%

Neurogene Key Statistics

in dollars & INR

Previous Close
$23.23
Open
$23.31
Today's High
$23.99
Today's Low
$22.9
Market Capitalization
$593.1M
Today's Volume
$188.5K
52 Week High
$74.49
52 Week Low
$14.44
Revenue TTM
$925.0K
EBITDA
$-65.5M
Earnings Per Share (EPS)
$-3.66
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-41.34%

How to invest in Neurogene from India?

It is very easy for Indian residents to invest directly in Neurogene from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Neurogene stock in both Indian Rupees (INR) and US Dollars (USD). Search for Neurogene or NGNE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Neurogene or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Neurogene shares which would translate to 0.037 fractional shares of Neurogene as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Neurogene, in just a few clicks!

Returns in Neurogene for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Neurogene investment value today

Current value as on today

₹90,965

Returns

₹9,035

(-9.04%)

Returns from Neurogene Stock

₹12,258 (-12.26%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Neurogene

-92%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Neurogene on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -92% less investors are searching Neurogene in the last 30 days versus the previous period.

Analyst Recommendation on Neurogene

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Neurogene(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
9
8
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Neurogene

What analysts predicted

Upside of 136.16%

Current:

$23.12

Target:

$54.60

Insights on Neurogene

  • Price Movement

    In the last 3 months, NGNE stock has moved down by -52.2%
  • NGNE vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 22.5%
  • NGNE vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 46.4%
  • Price to Sales

    ForNGNE every $1 of sales, investors are willing to pay $219.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Neurogene Technicals Summary

Sell

Neutral

Buy

Neurogene is currently in a neutral trading position according to technical analysis indicators.

Neurogene Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neurogene Inc
-0.34%
-39.35%
-11.82%
10.62%
-48.61%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neurogene Inc
NA
NA
NA
-4.41
-0.41
-0.32
NA
11.93
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neurogene Inc
Buy
$593.1M
-48.61%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Neurogene

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.
Organization
Neurogene
Employees
91
CEO
Dr. Rachel L. McMinn Ph.D.
Industry
Miscellaneous

Management People of Neurogene

NameTitle
Dr. Rachel L. McMinn Ph.D.
Founder, Executive Chair & CEO
Ms. Christine Mikail Cvijic J.D.
President, CFO & Corporate Secretary
Dr. Stuart Cobb Ph.D.
Chief Scientific Officer
Mr. Arvind Sreedharan
Senior Vice President of Business Operations
Ms. Donna M. Cochener-Metcalfe J.D.
Senior VP & General Counsel
Dr. Effie Albanis M.D.
Senior Vice President of Early Clinical & Translational Research
Dr. Andrew E. Mulberg CPI, FAAP, M.D.
Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
Mr. Ricardo Jimenez
Senior Vice President of Technical Operations
Dr. Julie Jordan M.D.
Chief Medical Officer

Important FAQs about investing in Neurogene from India :

What is Neurogene share price today?

Neurogene share price today stands at $23.12, Open: $23.31 ; Previous Close: $23.23 ; High: $23.99 ; Low: $22.90 ; 52 Week High: $74.49 ; 52 Week Low: $14.44. The stock opens at $23.31, after a previous close of $23.23. The stock reached a daily high of $23.99 and a low of $22.90, with a 52-week high of $74.49 and a 52-week low of $14.44.

Can Indians buy Neurogene shares?

Yes, Indians can invest in the Neurogene (NGNE) from India.

With INDmoney, you can buy Neurogene at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Neurogene at zero transaction cost.

How can I buy Neurogene shares from India?

It is very easy to buy Neurogene from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Neurogene be purchased?

Yes, you can buy fractional shares of Neurogene with INDmoney app.

What are the documents required to start investing in Neurogene stocks?

To start investing in Neurogene, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Neurogene

Today’s highest price of Neurogene (NGNE) is $23.99.

Today’s lowest price of Neurogene (NGNE) is $22.90.

What is today's market capitalisation of Neurogene

Today's market capitalisation of Neurogene NGNE is 593.1M

What is the 52 Week High and Low Range of Neurogene

  • 52 Week High

    $74.49

  • 52 Week Low

    $14.44

What are the historical returns of Neurogene?

  • 1 Month Returns

    -0.34%

  • 3 Months Returns

    -39.35%

  • 1 Year Returns

    -11.82%

  • 5 Years Returns

    -48.61%

Who is the Chief Executive Officer (CEO) of Neurogene

Dr. Rachel L. McMinn Ph.D. is the current Chief Executive Officer (CEO) of Neurogene.